Group 1 - MapLight Therapeutics, a biotechnology company based in Redwood City, California, plans to raise approximately $251 million through an IPO by issuing 14.8 million shares at a price of $17 per share, resulting in a fully diluted market capitalization of about $820 million [1] - The company focuses on developing innovative therapies for neuropsychiatric and central nervous system (CNS) diseases, with its main candidate drug ML-007C-MA aimed at treating schizophrenia and Alzheimer's disease psychosis (ADP) [2][3] - T. Rowe Price has committed to purchasing approximately $40 million worth of shares, representing 16% of the total offering, and MapLight plans to conduct an additional $8 million private placement with Goldman Sachs [1] Group 2 - Due to the current U.S. government shutdown, the SEC has paused the formal review of registration statements, prompting MapLight to utilize a rare provision under the Securities Act of 1933 to advance its listing process [2] - The company intends to price its shares 20 days after filing, but may reassess its strategy if the SEC resumes normal operations before October 26 [2] - MapLight was founded in 2018 and plans to list on NASDAQ under the ticker "MPLT," with Morgan Stanley, Jefferies, Leerink Partners, and Stifel serving as joint underwriters for the offering [3]